ScreenerHero

PHNPharmanutra S.p.A.

BIT · IT · Healthcare · Drug Manufacturers - Specialty & Generic · pharmanutra.it
81.10EUR-0.25%Mkt Cap: 846.15M $P/E: 36.95

Pharmanutra S.p.A., a nutraceutical company, engages in the research and development and marketing of food supplements and medical devices in Europe, the Middle East, Far East, North America, South America, and internati…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap846.15M $
Enterprise Value841.75M $
Revenue (TTM)151.02M $
Gross Profit111.81M $
Net Income (TTM)21.74M $
Revenue/Share15.81 USD
Last Price81.10 EUR
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees140
CountryIT
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINIT0005274094
Valuation
P/E (Trailing)36.95
P/E (Forward)26.67
PEG—
EV/EBITDA23.30
EV/Revenue5.57
P/S5.63
P/B10.53
EPS (TTM)2.20
EPS (Forward)3.06
52W Range
38.7574% of range95.90
52W High95.90 EUR
52W Low38.75 EUR
Profitability
Gross Margin77.38%
Oper. Margin15.62%
EBITDA Margin23.92%
Profit Margin15.05%
ROE28.03%
ROA15.97%
Growth
Revenue Growth25.60%
Earnings Growth44.00%
Cash Flow & Leverage
Operating CF21.26M $
CapEx (TTM)3.41M $
FCF Margin10.55%
FCF Yield1.88%
Net Debt-10.77M $
Net Debt/EBITDA-0.30
Balance Sheet
Debt/Equity0.29
Current Ratio2.38
Quick Ratio1.84
Book Value/Sh7.758 EUR
Cash/Share3.021 EUR
Dividends
Fwd Div Rate1.200 EUR
Trail. Div Rate1.200 EUR
Div. Yield1.47%
5Y Avg Yield1.43%
Payout Ratio45.45%
Ex-Div DateMay 4, 2026
Pay Date—
Analyst Consensus
Rating—
Target (Mean)81.33 EUR
Upside (mean)+0.3%
Target Range76.00 EUR – 86.00 EUR
€76.00+0.3% to mean€86.00
# Analysts3
Ownership
Shares Out.9.58M
Float3.28M
Insiders65.02%
Institutions16.25%
Technical
SMA 5085.58 (-5.2%)
SMA 20073.23 (+10.7%)
Beta0.17
S&P 52W Chg19.18%
Avg Vol (30d)7.37K
Avg Vol (10d)6.53K
Technical Indicators
RSI (14)39.5
MACD-1.0960
MACD Signal-0.8689
MACD Hist.-0.2270
BB Upper86.01 EUR
BB Middle83.15 EUR
BB Lower80.29 EUR
BB Width6.88%
ATR (14)2.130 EUR
Vol Ratio (20d)1.52x